VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...

Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...

Electricity bills are on track to rise an average of 8 percent nationwide by 2030 according to a June analysis from Carnegie ...

With heat and electricity bills on the rise, many households are falling behind on payments, according to a new analysis by ...

Americans now spend $532 billion annually on utilities, with median household costs reaching $4,168 a year New doxoINSIGHTS ...

More people are falling behind on paying their bills to keep on the lights and heat their homes, according to a new analysis of consumer data — a warning sign for the U.S. economy and another ...

Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer We used a Markov model to ...

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase ...

2020 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily-- New research on Drugs and Therapies - Monoclonal Antibodies is the subject of a report. According to news ...

At the tail end of this year’s legislative session in Albany, the Assembly and the Senate passed a bill that would repeal an ...